Top

Endocrine

Published in:

01-07-2018 | Mini Review

Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance

Authors: Felipe Vilaça Cavallari Machado, Fabio Pitta, Nidia Aparecida Hernandes, Gisele Lopes Bertolini

Published in: Endocrine | Issue 1/2018

Abstract

Purpose

Chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow obstruction that is associated with an abnormal chronic inflammatory response in the airways and lungs to noxious particles. COPD often leads to physical inactivity and deconditioning that added to inappropriate/excessive inflammatory responses leads to systemic consequences. Studies have shown that metabolic syndrome and manifested diabetes are more frequent in COPD than in healthy subjects; a possible explanation is that different pathophysiological aspects of COPD can lead to insulin resistance. Thus, this mini-review aims to present the main studies suggesting a pathophysiological relationship between COPD and insulin resistance.

Methods

A review of literature was conducted using PubMed and Web of Science databases with the aim of searching for studies supporting a relationship between COPD and insulin resistance.

Results

A physiopathological relationship between COPD and insulin resistance was found, supported in part due to common risk factors presented by these two conditions, such as smoking and physical inactivity. Also, systemic effects (worsening of physical inactivity and sedentary behavior, inflammation and oxidative stress, body composition abnormalities) and the corticosteroid treatment of patients with COPD may play a role.

Conclusion

Patients with COPD should be screened for abnormalities in insulin sensitivity in order to reduce morbidity and improve health status in this population.

Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2017). http://goldcopd.org. Accessed 21 Aug 2017

P.J. Miranda, R.A. DeFronzo, R.M. Califf, J.R. Guyton, Metabolic syndrome: definition, pathophysiology, and mechanisms. Am. Heart J. 149, 33–45 (2005)CrossRefPubMed

C.E. Bolton, M. Evans, A.A. Ionescu, S.M. Edwards, R.H.K. Morris, G. Dunseath et al., Insulin resistance and inflammation - a further systemic complication of COPD. COPD 4, 121–126 (2007)CrossRefPubMed

M. Minas, K. Kostikas, A.I. Papaioannou, P. Mystridou, E. Karetsi, P. Georgoulias et al., The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD 8, 414–420 (2011)CrossRefPubMed

S. Gläser, S. Krüger, M. Merkel, P. Bramlage, F.J.F. Herth, Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respiration 89, 253–264 (2015)CrossRefPubMed

P.J. Barnes, Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 138, 16–27 (2016)CrossRefPubMed

P.A. Kirkham, P.J. Barnes, Oxidative stress in COPD. Chest 144, 266–273 (2013)CrossRefPubMed

L. Lavie, P. Lavie, Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur. Respir. J. 33, 1467–1484 (2009)CrossRefPubMed

K.N. Keane, V.F. Cruzat, R. Carlessi, P.I.H. Bittencourt, P. Newsholme, Molecular events linking oxidative stress and inflammation to insulin resistance and ß-cell disfunction. Oxid. Med. Cell. Longev. 2015, 181643 (2015)CrossRefPubMedPubMedCentral

10.

S.E. Borst, The role of TNF-alpha in insulin resistance. Endocrine 23, 177–182 (2004)CrossRefPubMed

11.

J. Spranger, A. Kroke, M. Möhlig, K. Hoffmann, M.M. Bergmann, M. Ristow et al., Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into cancer and nutrition (EPIC)-Postdam study. Diabetes 52, 812–817 (2003)CrossRefPubMed

12.

H. Watz, B. Waschki, A. Kirsten, K.C. Müller, G. Kretschmar, T. Meyer et al., The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical activity. Chest 136, 1039–1046 (2009)CrossRefPubMed

13.

H. Watz, B. Waschki, T. Meyer, H. Magnussen, Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 33, 1165–1185 (2009)CrossRef

14.

F. Pitta, T. Troosters, M.A. Spruit, V.S. Probst, M. Decramer, R. Gosselink, Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171, 972–977 (2005)CrossRefPubMed

15.

N.A. Hernandes, D.C. Teixeira, V.S. Probst, A.F. Brunetto, E.M. Ramos, F. Pitta, Profile of the level of physical activity in the daily lives of patients with COPD in Brazil. J. Bras. Pneumol. 35, 949–956 (2009)CrossRefPubMed

16.

S.N.W. Vorrink, H.S.M. Kort, T. Troosters, J.W.J. Lammers, Level of daily physical activity in individuals with COPD compared with healthy controls. Respir. Res. 12, 33 (2011)CrossRefPubMedPubMedCentral

17.

N.M. Hamburg, C.J. Mcmackin, A.L. Huang, S.M. Shenouda, E. Michael, E. Schulz et al., Physical inactivity rapidly induces insulin resistance and microvascular dysfunction in healthy volunteers. Arter. Thromb. Vasc. Biol. 27, 2650–2656 (2008)CrossRef

18.

C.A. Stuart, R.E. Shangraw, M.J. Prince, E.J. Peters, R.R. Wolfe, Bed-rest induced insulin resistance occurs primarily in muscle. Metabolism 37, 802–806 (1988)CrossRefPubMed

19.

P.J. Arciero, D.L. Smith, J. Calles-escandon, Effects of short-term inactivity on glucose tolerance, energy expenditure, and blood flow in trained subjects. J. Appl. Physiol. 84, 1365–1373 (1998)CrossRefPubMed

20.

J. Smorawiński, H. Kaciuba-Uściłko, K. Nazar, P. Kubala, E. Kamińska, A.W. Ziemba et al., Effects of three-day bed rest on metabolic, hormonal and circulatory responses to an oral glucose load in endurance or strength trained athletes and untrained subjects. J. Physiol. Pharmacol. 51, 279–289 (2000)PubMed

21.

A.A.M. Castro, C. Kümpel, R.C. Rangueri, M.D. Oliveira, R.A. Dornelles, E.R. Brito et al., Daily activities are sufficient to induce dynamic pulmonary hyperinflation and dyspnea in chronic obstructive pulmonary disease patients. Clinics 67, 319–325 (2012)CrossRefPubMedPubMedCentral

22.

M. Velloso, N.H. do Nascimento, M.R. Gazzotti, J.R. Jardim, Evaluation of effects of shoulder girdle training on strength and performance of activities of daily living in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 8, 187–192 (2013)PubMedPubMedCentral

23.

N.C. Lipovec, R.J.H.C.G. Beijers, B. van den Borst, W. Doehner, M. Lainscak, A.M.W.J. Schols, The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD 13, 399–406 (2016)CrossRef

24.

S.K. Park, J.L. Larson, The relationship between physical activity and metabolic syndrome in people with chronic obstructive pulmonary disease. J. Cardiovasc. Nurs. 29, 499–507 (2014)CrossRefPubMedPubMedCentral

25.

M.A. Spruit, S.J. Singh, C. Garvey, R. Zu Wallack, L. Nici, C. Rochester et al., An official american thoracic society/european respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 188, e13–e64 (2013)CrossRefPubMed

26.

P. Joppa, R. Tkacova, F.M.E. Franssen, C. Hanson, S.I. Rennard, E.K. Silverman et al., Sarcopenic obesity, functional outcomes, and systemic inflammation in patients with chronic obstructive pulmonary disease. J. Am. Med. Dir. Assoc. 17, 712–718 (2016)CrossRefPubMed

27.

G.H. Goossens, The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol. Behav. 94, 206–218 (2008)CrossRefPubMed

28.

A.R. Saltiel, C.R. Kahn, Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001)CrossRefPubMed

29.

R.J.H.C.G. Beijers, C. van de Bool, B. van den Borst, F.M.E. Franssen, E.F.M. Wouters, A.M.W.J. Schols, Normal weight but low muscle massa and abdominally obese: implications for the cardiometabolic risk profile in chronic obstructive pulmonary disease. J. Am. Med. Dir. Assoc. 18, 533–538 (2017)CrossRefPubMed

30.

C.E. Wells, M.I. Polkey, E.H. Baker, Insulin resistance is associated with skeletal muscle weakness in COPD. Respirology 21, 689–696 (2016)CrossRefPubMed

31.

V.V.A. Lira, C.R.C. Benton, Z. Yan, A. Bonen, PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 299, E145–E161 (2010)CrossRefPubMedPubMedCentral

32.

F. Maltais, M. Decramer, R. Casaburi, E. Barreiro, Y. Burelle, R. Debigaré et al., An official American thoraic society/European respiratory society statement: update on lim muscle dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 189, 15–62 (2014)CrossRef

33.

H.J. Green, M.E. Burnett, C.L. D’Arsigny, D.E. O’Donnell, J. Ouyang, K.A. Webb, Altered metabolic and transporter characteristics of vastus lateralis in chronic obstructive pulmonary disease. J. Appl. Physiol. 105, 879–886 (2008)CrossRefPubMed

34.

B.K. Pedersen, M.A. Febbraio, Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8, 457–465 (2012)CrossRefPubMed

35.

K.H. Park, L. Zaichenko, M. Brinkoetter, B. Thakkar, A. Sahin-Efe, K.E. Joung et al., Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 98, 4899–4907 (2013)CrossRefPubMed

36.

N. Ijiri, H. Kanazawa, K. Asai, T. Watanabe, K. Hirata, Irisin, a newly discovered myokine, is a novel biomaker associated with physical activity in patients with chronic obstructive pulmonary disease. Respirology 20, 612–617 (2015)CrossRefPubMed

37.

E.B. Geer, J. Islam, C. Buettner, Mechanisms of glucocorticoid-induced insulin resistance. Endocrinol. Metab. Clin. North Am. 43, 75–102 (2014)CrossRefPubMedPubMedCentral

38.

H. Schäcke, W.D. Döcke, K. Asadullah, Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23–43 (2002)CrossRefPubMed

39.

D. Blackburn, J. Hux, M. Mamdani, Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J. Gen. Intern. Med. 17, 717–720 (2002)CrossRefPubMedPubMedCentral

40.

D.E. Niewoehner, M.L. Erbland, R.H. Deupree, D. Collins, N.J. Gross, R.W. Light et al., Effects of systemic glucocoricoids on exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 340, 1941–1947 (1999)CrossRefPubMed

41.

S. Suissa, A. Kezouh, P. Ernst, Inhaled corticosteroids and the risk of diabetes onset and progression. Am. J. Med. 123, 1001–1006 (2010)CrossRefPubMed

42.

P.M. O’Byrne, S. Rennard, H. Gerstein, F. Radner, S. Peterson, B. Lindberg et al., Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir. Med. 106, 1487–1493 (2012)CrossRefPubMed

43.

N. Dendukuri, L. Blais, J. LeLorier, Inhlaed corticosteroids and the risk of diabetes among the elderly. Br. J. Clin. Pharmacol. 54, 59–64 (2002)CrossRefPubMedPubMedCentral

44.

F.S. Facchini, C.B. Hollenbeck, J. Jeppesen, Y.D. Chen, G.M. Reaven, Insulin resistance and cigarette smoking. Lancet 339, 1128–1130 (1992)CrossRefPubMed

45.

A.C. Frati, F. Iniestra, C.R. Ariza, Acute effect of cigarette smoking on glucose tolerance and other cardiovascular risk factors. Diabetes Care 19, 112–118 (1996)CrossRefPubMed

46.

H. Cena, A. Tesone, R. Niniano, I. Cerveri, C. Roggi, G. Turconi, Prevalence rate of metabolic syndrome in a group of light and heavy smokers. Diabetol. Metab. Syndr. 5, 1–7 (2013)CrossRef

47.

J.E. Manson, U.A. Ajani, S. Liu, D.M. Nathan, C.H. Hennekens, A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am. J. Med. 109, 538–542 (2000)CrossRefPubMed

48.

C. Willi, P. Bodenmann, W.A. Ghali, P.D. Faris, J. Cornuz, Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298, 2654–2664 (2007)CrossRefPubMed

49.

K. Sun, J. Liu, G. Ning, Active smoking and the risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS ONE 7, e47791 (2012)CrossRefPubMedPubMedCentral

50.

B.C. Bergman, L. Perreault, D. Hunerdosse, A. Kerege, M. Playdon, A.M. Samek et al., Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 61, 3156–3166 (2012)CrossRefPubMedPubMedCentral

51.

T. Wada, M. Urashima, T. Fukumoto, Risk of metabolic syndrome persists twenty years after the cessarion of smoking. Intern. Med. 46, 1079–1082 (2007)CrossRefPubMed

52.

G. Piazzolla, A. Castrovilli, V. Liotino, M.R. Vulpi, M. Fanelli, A. Mazzocca et al., Metabolic syndome and chronic obstructive pulmonary disease (COPD): the interplay among smoking, insulin resistance and vitamin D. PLoS ONE 12, e0186708 (2017)CrossRefPubMedPubMedCentral

53.

R.J. Dennis, D. Maldonado, M.X. Rojas, P. Aschner, M. Róndon, L. Charry et al., Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm. Med. 10, 38 (2010)CrossRefPubMedPubMedCentral

54.

D.A. Lawlor, S. Ebrahim, G.D. Smith, Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women’s Heart and Health Study. Diabetologia 47, 195–203 (2004)CrossRefPubMed

55.

S. Singh, M. Bodas, N.K. Bhatraju, B. Pattnaik, A. Gheware, P.K. Parameswaran et al., Hyperinsulinemia adversely affects lung structure and function. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L837–L845 (2016)CrossRefPubMedPubMedCentral

Title: Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance
Authors: Felipe Vilaça Cavallari Machado
Fabio Pitta
Nidia Aparecida Hernandes
Gisele Lopes Bertolini
Publication date: 01-07-2018
Publisher: Springer US
Published in: Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1554-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Comment on Microsurgical therapy of pituitary adenomas

Kisspeptin and LH pulsatile temporal coupling in PCOS patients

Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study

Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?

Alteration in skeletal muscle mass in women with subclinical hypercortisolism

Comparison of peripheral nerve protection between insulin-based glucose control and alpha lipoic acid (ALA) in the streptozotocin (STZ)-induced diabetic rat

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page